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Background: Chronic kidney disease affects approximately one in ten North Americans and is associated with a
high risk of cardiovascular disease. Chronic kidney disease in women is characterized by an abnormal sex hormone
profile and low estradiol levels. Since low estradiol levels are associated with an increased cardiovascular risk in
healthy women, our objective is to determine the effect of hormone therapy on all-cause mortality, cardiovascular
mortality, and cardiovascular morbidity in women with chronic kidney disease.
Methods/design: Studies examining hormone therapy for adult women with chronic kidney disease will be included.
The primary outcome is all-cause or cardiovascular mortality and morbidity. We will search electronic bibliographic
databases (MEDLINE, EMBASE, and the Cochrane Central Register of Controlled Trials (CENTRAL)) along with relevant
conference proceedings, table of contents of journals, and review articles. Two investigators will independently screen
identified abstracts and select observational cohort studies, case–control studies, and randomized controlled trials
examining hormone therapy in women with chronic kidney disease. These investigators will also independently
abstract data from relevant full-text journal articles and assess risk of bias. Where possible, these data will be
summarized using pooled or combined estimates for the risk ratio or hazard ratio of all-cause mortality, cardiovascular
mortality, and cardiovascular morbidity in women with chronic kidney disease with and without hormone therapy.
A random effects model will be used, and meta-regression and subgroup analyses will be used to explore potential
source of heterogeneity.
Discussion: Given the high burden of cardiovascular disease in women with chronic kidney disease, this study will help
guide clinical practice by summarizing current evidence on the use of hormone therapy for prevention of all-cause
mortality, cardiovascular mortality, and cardiovascular morbidity in this population.
Systematic review registration: The final protocol was registered with PROSPERO (CRD42014014566).
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Table 1 PECOD question for the systematic review
Population Women with chronic kidney disease (as defined by eGFR or
presence of kidney damage)
Exposure Hormone Therapy (HT) (all types of HT including
estradiol alone or estradiol and progesterone)
Comparator Placebo or No HT
Outcome All-cause and cardiovascular mortality
Design RCTs, cohort, and case–control studies
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Chronic kidney disease (CKD) is a prevalent condition
with a high burden of all-cause and cardiovascular (CV)
morbidity and mortality [1,2]. Women with CKD have an
abnormal sex hormone profile characterized by the lack of
pulsatile gonadotropin-releasing hormone (GnRH) secre-
tion and low estradiol levels [3,4]. As a low estrogen state
is associated with increased CV risk [5], it may contribute
to the increase in CV morbidity and mortality observed in
women with CKD.
There is significant epidemiological evidence suggesting
a cardioprotective function for ovarian sex hormones and,
in particular, estradiol in women [6-12]. For example, the
prevalence of cardiovascular disease (CVD) increases with
age in men; however, women are relatively protected until
menopause, after which time morbidity and mortality
from CVD equal or exceed that of men [13]. Randomized
control trials demonstrated no evidence of cardioprotec-
tion with hormone therapies [14-16]; however, later ana-
lysis of these studies have shown that the timing of
hormone therapy initiation [17], route of administration
of estrogen [18], and the type of estrogen and proges-
terone used [19] impact CV risk significantly.
In women with CKD, disruptions in the GnRH produc-
tion lead to a hypoestrogenic state and cessation of men-
ses and infertility, both of which return to normal levels
with successful kidney transplants [20-23]. There is evi-
dence to suggest that this loss of estradiol in women with
CKD is associated with increased CV risk. In contrast to
healthy women [24], women with end-stage kidney disease
(ESKD) have similar overall mortality rates compared to
age-matched men [25-27]. It is hypothesized that this in-
creased risk may be due to the lower lifetime exposure to
estradiol as a result of onset of kidney disease earlier in life
[26]. In amenorrheic women with CKD, estrogen therapy
has favorable effects on lipid profiles by decreasing LDL
levels and increasing HDL levels [28-30].
Although a recent meta-analysis of postmenopausal
hormone therapy in healthy postmenopausal women found
no evidence of cardioprotection, the results varied among
the included studies due to the different hormone regi-
mens, the timing of hormone therapy initiation, and
the type of estradiol and progestin used [19,31]. Add-
itionally, it is important to note that 8 of the 13 trials
included in the meta-analysis were examining the effect
of hormone therapy as secondary, rather than primary,
prevention in a high CV-risk population [31]. Whether
these results are translatable to a high CV-risk population
with CKD-mediated low levels of estradiol is unclear as
the evidence has not been systematically summarized.
Given the paucity of work on the therapeutic role of hor-
mone therapy in the CKD population, we propose to
complete a systematic review to determine the effect of
hormone therapy on all-cause mortality, cardiovascularmortality, and cardiovascular morbidity in women with
CKD. Additionally, given that the timing of the admin-
istration of hormone therapy (perimenopausal vs post-
menopausal) influences risk, we aim to determine whether
age, a surrogate for menopausal status, at administration




The systematic review protocol was designed based on the
guidance from the Preferred Reporting Items for System-
atic reviews and Meta-analyses Protocol (PRISMA-P) [33].
Protocol
To determine the effect of hormone therapy on all-
cause mortality, cardiovascular mortality, and cardio-
vascular morbidity (as defined by individual studies) in
women with CKD, we developed a systematic review
and meta-analysis protocol using the Cochrane guide-
lines for systematic review and meta-analysis [34].
The final protocol was registered with PROSPERO
(CRD42014014566) [35]. The population, exposure, com-
parator, outcome, and study design (PECOD) utilized
within this systematic review are presented in Table 1.
Search strategy
Bibliographic databases
The online databases to be searched are MEDLINE
(1950 to September 2014), EMBASE (1980 to September
2014), and the Cochrane Central Register of Controlled
Trials (CENTRAL). The Medline search will be peer
reviewed [36].Other sources
Two individuals will search the reference list of relevant
publications, abstracts of all major North American Neph-
rology and Cardiovascular meetings, (American Society of
Nephrology, Canadian Society of Nephrology, American
Heart Association Scientific Sessions and American
College of Cardiology) between 2011 and 2014, and
the tables of contents of major nephrology journals
(Journal of American Society of Nephrology, Kidney
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and cardiology journals (Circulation, Journal of the
American College of Cardiology) from January 2011 to
September 2014. In order to get information about on-
going or unpublished studies, experts in the field will be
contacted. Experts will be identified through the abstract
review process.
Search limits
The search of online databases will include all languages
and will not be restricted based on time period; however,
it will be limited to studies on humans.
Search terms
Two separate searches will be conducted:
The first search will include the population and exposure
terms of the PECOD question (Table 2):
Chronic kidney disease
The first Boolean search will be done using the “OR”
term to combine “exploded” MeSH subject headings and
“text word” searches of the following:
“Renal insufficiency chronic”, “Kidney Failure”,
“Kidney Diseases”, “Renal Replacement Therapy”,
“Uremia”, “Dialysis”, “Hemodialysis”, “Hemofiltration”,
“Peritoneal Dialysis”, “Predialysis”, “Kidney/Renal
Transplant”, “Kidney/Renal Allograft”, “End Stage
Renal/Kidney”, “Chronic Kidney Failure” or “Chronic
Kidney Disease”
Hormone therapy
The second Boolean search will be done using the “OR”
term to combine “exploded” MeSH subject headings and
“text word” searches for the following:
“Hormone Therapy”, “Hormone Replacement
Therapy”, “Estrogen Replacement Therapy”,
“Estrogen”, “Estradiol”, “Estriol”, “Conjugated Equine
Estrogen”, “Progesterone”, “Progestin”,
“Medroxyprogesterone acetate” or “Dydrogesterone”
The above two will be combined using the “AND term.
The second search will include the exposure, outcome,
and design terms of the PECOD question (Table 3). The
purpose of this search is to identify randomized con-
trolled trials that included subjects with CKD and con-
ducted subgroup analysis for these subjects.
Hormone therapy
The first Boolean search will be done using the “OR”
term to combine “exploded” MeSH subject headings and
“text word” searches for the following:“Hormone therapy”, “Hormone Replacement
Therapy”, “Estrogen Replacement Therapy”,
“Estrogen”, “Estradiol”, “Estriol”, “Conjugated Equine
Estrogen”, “Progesterone”, “Progestin”,
“Medroxyprogesterone acetate”, or “Dydrogesterone”
Cardiovascular disease and all-cause mortality
The second Boolean search will be done using the “OR”
term to combine “exploded” MeSH subject headings and
“text word” searches for the following:
“Cardiovascular Diseases”, “Stroke”, “Hypertension”,
“Hyperlipidemias”, “Arteriosclerosis”, “Cholesterol”
“Blood Pressure”, “Coronary Heart Disease”,
“Mortality”, “Survival Rate”, “All Cause Mortality”,
“Cause of Death”, or “Death”
Randomized control trial
The third Boolean search will be done using the “OR”
term to combine “exploded” MeSH subject headings and
“text word” searches for the following:
“Randomized Controlled Trial”, “Controlled Clinical
Trial”, “Placebo”, or “Drug Therapy”
The above three will be combined using the “AND” term.
Additionally, articles with the terms “Fabry’s Disease” and
“Growth Hormone Therapy” in the title or abstract will be
excluded.
Identification of articles for eligibility
Initial screening
After a calibration exercise in order to identify any sys-
tematic discrepancies in classification of abstracts be-
tween the two reviewers, screening will be conducted by
two independent reviewers to determine articles eligible
for the systematic review. An initial screen of identified
abstracts from the databases and other sources will be
performed to identify relevant articles for a full-text re-
view. An abstract from the search will be considered for
a full-text review if it meets the PECOD question cri-
teria. This initial screening is intended to be sensitive
and broadly capture any relevant articles studying hor-
mone therapy in women with chronic kidney disease. In
order to provide a comprehensive systematic review of
the topic, the search and eligibility will not be restricted
by a specific geographic region or publication year.
The decision of each reviewer for each abstract will be
recorded, and any disagreement between reviewers will
be resolved by consensus at all stages of the screening
process. Authors will be contacted for missing data or
clarification. For the initial screening search, if there is a
lack of consensus among the reviewers and one of the
Table 2 Search strategy for the chronic kidney disease
and hormone replacement therapy search
Population and Exposure terms of the PECOD question
1 Exp hormone replacement therapy/
2 Hormone replacement therap$.tw.
3 (HRT or ERT or ORT).ti,ab.
4 Exp estrogen replacement therapy/
5 (Hormone adj3 replacement adj3 therap$).mp.
6 (?Estrogen adj3 replacement adj3 therap$).mp.
7 ?Estrogen replacement therap$.tw.
8 ?Estradiol replacement therap$.tw.
9 Hormone therap$.tw.
10 Postmenopausal hormone therap$.tw.
11 Post-menopausal hormone therap$.tw.














26 22 or 23 or 24 or 25
27 or/13-21
28 26 and 27
29 12 or 28
30 Exp kidney failure/
31 Exp chronic kidney failure/
32 Exp renal insufficiency/
33 Exp renal insufficiency, chronic/
34 Exp chronic kidney disease/
35 Exp kidney disease/
36 Exp renal replacement therapy/
37 Exp uremia/
38 Exp hemodialysis/
39 Exp kidney transplantation/
40 (Haemodialys* or hemodialys*).tw.
41 Dialysis.tw.
42 Peritoneal dialysis.tw.
43 Exp peritoneal dialysis/
Table 2 Search strategy for the chronic kidney disease
and hormone replacement therapy search (Continued)
44 (CAPD or CCPD or APD).tw.





50 (H?emodia* or h?emofiltr*).tw.
51 (Pre-dialysis or predialysis).tw.
52 (Kidney transplant* or renal transplant*).tw.
53 (Kidney allograft* or renal allograft*).tw.
54 (Kidney graft* or renal graft*).tw.
55 (End-stage renal or end-stage kidney or endstage renal or endstage
kidney).tw.
56 (ESRF or ESKF or ESRD or ESKD).tw.
57 (CKF or CKD or CRF or CRD).tw.
58 or/30-57
59 29 and 58
60 Limit 59 to animals
61 Limit 59 to (Animals and humans)
62 60 not 61
63 59 not 62
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in question will qualify for a full-text review.
Full-text review
The same two individuals will scan full-text articles, and
those that meet the following criteria will be considered
for the systematic review:
 Population: The study includes women with chronic
kidney disease
 Exposure: Hormone therapy
 Comparator: Placebo or no hormone therapy
 Outcome: Hazards or risks of all-cause and cardio-
vascular mortality
 Study Design: RCT, cohort study, or case–control
study
This will capture trials and cohort and case–control
studies that compare hormone therapy to placebo or no
hormone therapy on the risks or hazards of all-cause mor-
tality, cardiovascular mortality, and cardiovascular mor-
bidity in women with CKD for potential meta-analysis.
The decision of each reviewer will be documented, and
the agreement between the reviewers will be quantified by
the Kappa statistic. Any disagreement between reviewers
will be resolved by consensus.
Table 3 Search strategy for the cardiovascular disease
and hormone replacement therapy and randomized
control trial search
Exposure, outcome, and design terms of the PECOD question
















17 (Sick adj sinus).tw.
18 Exp Stroke/




23 (Brain adj2 accident*).tw.
24 ((Brain* or cerebral or lacunar) adj2 infarct*).tw.
25 Exp hypertension/
26 (Hypertension$ or hypertensive$).tw.
27 Peripheral arter* disease*.tw.













41 Exp hormone replacement therapy/
42 Hormone replacement therap$.tw.
Table 3 Search strategy for the cardiovascular disease
and hormone replacement therapy and randomized
control trial search (Continued)
43 (HRT or ERT or ORT).ti,ab.
44 Exp estrogen replacement therapy/
45 (Hormone adj3 replacement adj3 therap$).mp.
46 (?Estrogen adj3 replacement adj3 therap$).mp.
47 ?Estrogen replacement therap$.tw.
48 ?Estradiol replacement therap$.tw.
49 Hormone therap$.tw.
50 Postmenopausal hormone therap$.tw.
51 Post-menopausal hormone therap$.tw.














66 62 or 63 or 64 or 65
67 or/53-61
68 66 and 67
69 52 or 68
70 Randomized controlled trial.pt.







78 70 or 71 or 72 or 73 or 74 or 75 or 76 or 77
79 Limit 78 to animals
80 Limit 78 to (animals and humans)
81 79 not 80
82 78 not 81
83 Exp mortality/
84 Exp survival rate/
85 All cause mortality.tw.
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Table 3 Search strategy for the cardiovascular disease
and hormone replacement therapy and randomized
control trial search (Continued)
86 Mortality.tw.
87 Cause of death.tw.
88 Exp death/
89 Death.tw.
90 Exp “Cause of death”/
91 Survival rate.tw.
92 83 or 84 or 85 or 86 or 87 or 88 or 89 or 90 or 91
93 40 or 92
94 69 and 82 and 93
95 Fabry.tw.
96 Fabry’s.tw.
97 95 or 96
98 Growth hormone.tw.
99 97 or 98
100 94 not 99
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A data extraction form will be developed to record and
analyze information from each of the identified studies.
The data will be extracted and verified by both reviewers in
order to decrease reviewer error and bias. Data will be
abstracted on study identification (authors, year of publica-
tion, and location of centers), characteristics of study design
(sample size, inclusion and exclusion criteria, length of
follow-up, type of hormone therapy, dosage of hormone
therapy), characteristics of study participants (mean/median
age, presence of comorbidities, stage of CKD, mean glom-
erular filtration rate (GFR), duration of CKD, time on
dialysis), and outcome variable of interest (risk of all-cause
mortality, cardiovascular mortality, and cardiovascular mor-
bidity). Outcomes of RCTs and observational studies will
be recorded separately. The data will be organized and
managed in Endnote (version X7, Thomson Reuters,
New York, NY) and Excel (version 2007, Microsoft
Corporation, Redmond, WA).
Risk of bias assessment
Each study will be appraised for quality and risk of bias by
each reviewer using the Cochrane risk of bias tool for ran-
domized controlled trials for RCTs or the Cochrane risk
of bias tool for cohort studies [37]. Additionally, a Jadad
score will be calculated for each trial [38]. This will be
used to determine the strength of the body of evidence.
Data synthesis and analysis
Data will be presented on the number and characteristic
of articles identified for the initial screening and full-text
review. The number of identified studies that wereincluded and excluded (with reasons for exclusions)
will be presented using the PRISMA flow chart [39].
The primary outcome of the risk ratio of all-cause mor-
tality, cardiovascular mortality, and cardiovascular mor-
bidity with hormone therapy compared to placebo or no
hormone therapy will be reported from a potential meta-
analysis of the RCTs and observational studies. If only the
hazard ratio is presented, the number of events in each
group will be abstracted from the study (if possible) and a
risk ratio will be presented. If the above is not possible, we
will present both risk ratio and hazard ratio estimates sep-
arately. The estimates will be presented separately for
RCT and observational studies. As we anticipate the stud-
ies to be inherently different due to types of hormone
therapy, dose regimen, etc., we will use the random effects
model to pool estimates. Furthermore, statistical hetero-
geneity will be assessed using the Cochrane Q statistic and
I2 statistic. If there is significant statistical heterogeneity,
univariate meta-regression analysis will be done to assess
the effects of the following variables on risk estimates:
mean age, diabetes, cardiac history, comorbidities, mean
estimated glomerular filtration rate, CKD stage, and route
of administration of hormone therapy. Evidence of publica-
tion bias will be determined through visual inspection of
funnel plots and Begg’s rank correlation test for asymmetry.
All analysis will be performed using STATA (version 12,
StataCorp LP, College Station, TX). If meta-analysis is not
possible, we will present the results as a systematic review.
Limitations
Although this methodology had been designed to mi-
nimize bias, we anticipate some limitations with this
review. First, we anticipate a difference in the formulation
and dosage of hormone therapy in different studies. Re-
striction of the inclusion criteria to a specific formula-
tion or dosage of hormone therapy would likely result
in a paucity of data. Therefore, in order to control for
any variations in outcomes due to differences in type
and dose of hormone therapy in the included studies,
we will perform subgroup analyses based on the type
and doses of hormone therapy used to understand their
contribution to heterogeneity.
Second, our results may be confounded by the lack of
study-level data on the prevalence of important comor-
bidities such as diabetes and hypertension. Due to this,
our results would have to be interpreted with caution;
however, we will attempt to provide sufficient evidence
to help determine the clinical significance of the pre-
sented pooled estimates by conducting stratified analyses
when possible.
Discussion
In summary, this systematic review has the potential to
have significant clinical implications. If a cardioprotective
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vide a rationale for large multicenter RCTs to examine es-
trogen replacement as a therapy to mitigate the high CV
risk in women with CKD. Conversely, if the cardioprotec-
tive effects of hormone therapy cannot be established, this
evidence would be useful in enhancing both patients’
and physicians’ understanding of the limitations of this
treatment.
To ensure that our findings have clinical impact on both
patients and the physicians who care for them, we will dis-
seminate our findings broadly by presenting at scientific
conferences, publishing in a peer-reviewed journal as well
as newsletters and websites of interested organizations,
and conducting meetings with key stakeholders.
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